Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer
Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.
Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.
The randomized phase II study compared IMM-101, a bacterially derived systemic immunomodulator, in combination with gemcitabine with gemcitabine alone. The patient population was deemed ineligible to receive FOLFIRINOX or nab-paclitaxel (Abraxane). The majority of patients had metastatic disease, Dalgleish adds.
Results showed that the combination demonstrated an increase in survival over gemcitabine alone. IMM-101 is an injectable drug with no obvious additive toxicities, making it a novel agent in the first-line setting for the treatment of pancreatic cancer, Dalgleish explains.
